Purpose

The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.

Condition

Eligibility

Eligible Ages
Between 40 Years and 78 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subject ≥40 and ≤78 years of age at the time of consent;
  • Women of child bearing potential must not be pregnant, evidenced by a negative pregnancy test (blood or urine) pre-treatment, or lactating and agree not to become pregnant for the duration of the study;
  • Smoking history of at least 10 pack years;
  • Not smoking or using any other inhaled substance (e.g., cigarettes, vaping, cannabis, pipes) for a minimum of 2 months prior to consent and agrees to not start for the duration of the study;
  • Subject has received a flu vaccination within the 12 months prior to the procedure or agrees to obtain vaccination once it becomes available and agrees to annual vaccinations for the duration of the study;
  • Resting SpO2 ≥89% on room air at the time of screening;
  • CAT score ≥10 at the time of screening;
  • Diagnosis of COPD with 30%≤ FEV1 ≤60% of predicted and FEV1/FVC <70% (post-bronchodilator);
  • Documented history of ≥ 2 moderate COPD exacerbations or ≥ 1 severe COPD exacerbation leading to hospitalization in the 12 months prior to consent;
  • Subject has a documented history of having minimally been taking a LAMA and a LABA as regular respiratory maintenance medication for ≥12 months at the time of consent;
  • If subject has participated in pulmonary rehabilitation, program must have been completed ≥3 months prior to consent; if in a maintenance program, subject agrees to continue their current program through their 12-month follow-up visit;
  • Subject is a candidate for bronchoscopy in the opinion of the physician or per hospital guidelines;
  • The subject is willing, able and agrees to complete all protocol required baseline and follow-up testing assessments including taking certain medications (e.g., azithromycin, prednisolone/prednisone);
  • Subject has provided written informed consent using a form that has been reviewed and approved by the Institutional Review Board (IRB)/Ethics Committee (EC).

Exclusion Criteria

  • Body Mass Index <18 or >35;
  • Subject has an implantable electronic device;
  • Uncontrolled diabetes as evidenced by an HbA1c >7 %;
  • Pulmonary nodule thought to be at high risk of malignancy;
  • Malignancy treated with radiation or chemotherapy within 2 years of consent;
  • More than 3 respiratory related hospitalizations within 1 year of consent;
  • Asthma as defined by the current Global Initiative for Asthma (GINA) guidelines;
  • Subject diagnosed with a dominant non-COPD lung disease or condition which affects the lungs (e.g., cystic fibrosis, paradoxical vocal cord motion, eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillosis, interstitial lung disease or active tuberculosis) or has a documented medical history of pneumothorax within 2 years of consent;
  • Clinically relevant bronchiectasis, defined as severe single lobe or multilobar broncial wall thickening associated with airway dilation on CT scan leading to cough and tenacious sputum on most days;
  • Known pre-existing diagnosis of pulmonary hypertension, defined as clinical evidence of pulmonary hypertension (i.e. cardiovascular function impairment including peripheral edema) and a sustained elevation of the mean pulmonary artery pressure ≥25 mmHg at rest by right heart catheterization or estimated right ventricular systolic pressure >40 mmHg by echocardiogram;
  • Myocardial infarction within last 6 months, EKG with evidence of life threatening arrhythmias or acute ischemia, pre-existing documented evidence of an LVEF <45%, stage C or D (ACC/AHA) or Class III or IV (NYHA) congestive heart failure, or any other past or present cardiac findings that make the subject an unacceptable candidate for a bronchoscopic procedure utilizing general anesthesia;
  • Subjects who have had abdominal surgical procedure(s) on the stomach, esophagus or pancreas performed ≤2 years of consent or have ongoing related symptoms within the past year;
  • Subjects with symptomatic gastric motility disorder(s) (e.g., gastroparesis) as evidenced by a GCSI score ≥18.0 or with severe GERD (e.g., refractory heartburn, endoscopic esophagitis) or severe dysphagia (e.g., esophageal stricture, achalasia, esophageal spasm);
  • The subject has any disease or condition that might interfere with completion of a procedure or this study (e.g., structural esophageal disorder, life expectancy <3 years);
  • Prior lung or chest procedure (e.g., lung transplant, LVRS, BLVR, lung implant, metal stent, valves, coils, median sternotomy, bullectomy, lobectomy or segmentectomy or other interventional lung procedure performed ≤1 year of consent); NOTE: Segmentectomy for benign lesion or segmentectomy for non-recurrent cancer ≥2 years is allowed. Vascular stents allowed if implanted ≥3 months and ≥5 mm away from the anticipated treatment location(s). Subjects with explanted lung valve(s) allowed if ≥3 months and meet all other enrollment criteria.
  • Daily use of >10 mg of prednisone or its equivalent at the time of consent;
  • Recent (within 3 months of consent) opioid use;
  • Known contraindication or allergy to medications required for bronchoscopy or general anesthesia (e.g., lidocaine, atropine, propofol, sevoflurane) that cannot be medically controlled;
  • Baseline chest CT scan reveals bronchi anatomy cannot be fully treated with available catheter sizes, presence of severe emphysema >50%, lobar attenuation area or severe bullous disease (>1/3 hemithorax) (as determined by the CT core lab using a single density mask threshold of -950 HU) or site discovery of a mass that requires treatment;
  • In the opinion of the treating Investigator, use of the Nuvaira System is not technically feasible due to subject anatomy or other clinical finding (e.g., acute pneumothorax, pleural effusion);
  • Patient is currently enrolled in another clinical trial that has not completed follow-up.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Subjects will be randomized with equal allocation (1:1) into two arms: TLD therapy plus optimal medical care (Active Treatment) and optimal medical care (Sham Control). Randomization of patients on an inhaled corticosteroid will be stratified.
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)
Masking Description
Subject and assessor double-blinding will be maintained through 1 year post-procedure.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Active Treatment
Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
  • Device: Targeted Lung Denervation (TLD)
    Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
    Other names:
    • TLD, TLD Therapy
  • Other: Optimal Medical Care
    Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
Sham Comparator
Sham Control
Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
  • Other: Optimal Medical Care
    Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).

Recruiting Locations

University of Alabama at Birmingham (UAB) Lung Health Center
Birmingham, Alabama 35294
Contact:
Patti Smith
205-996-5392
patriciasmith@uabmc.edu

More Details

Status
Recruiting
Sponsor
Nuvaira, Inc.

Study Contact

Delanie Reller
(763) 450-5673
dreller@nuvaira.com

Detailed Description

The primary objective of this study is to evaluate the efficacy of targeted lung denervation (TLD) in addition to optimal medical care to reduce moderate or severe exacerbation's and related hospitalizations, compared with optimal medical care alone, in patients with chronic obstructive pulmonary disease (COPD).

The secondary objective is to evaluate the long-term safety and other efficacy assessments of targeted lung denervation (TLD) in addition to optimal medical care compared with optimal medical care alone.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.